NCT04415749View on ClinicalTrials.gov

NasoShield in Healthy Adults to Study Safety and Immunogenicity

PHASE1CompletedINTERVENTIONAL

Enrollment

43

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

March 15, 2021

Study Completion Date

March 15, 2021

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

NasoShield

NasoShield is an adenovirus-vectored anthrax vaccine

OTHER

Placebo

Normal saline

Trial Locations (1)

84107

JBR Clinical Research, Salt Lake City

Sponsors

Lead Sponsor

Altimmune, Inc.

All Listed Sponsors

collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Altimmune, Inc.

INDUSTRY

NCT04415749 - NasoShield in Healthy Adults to Study Safety and Immunogenicity | Biotech Hunter | Biotech Hunter